Discovery and Development of HDAC Inhibitors : Approaches for the Treatment of Cancer a Mini-review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Histone deacetylase (HDAC) inhibitors have emerged as promising cancer therapeutics due to their ability to induce differentiation, cell cycle arrest, and apoptosis in cancer cells. In the present review, we have described the systemic discovery and development of HDAC inhibitors. Researchers across the globe have identified various small molecules like benzo[d][1,3]dioxol derivatives, belinostat analogs, pyrazine derivatives, quinazolin- 4-one-based derivatives, 2,4-imidazolinedione derivatives, acridine hydroxamic acid derivatives, coumarin derivatives, tetrahydroisoquinoline derivatives, thiazole-5-carboxamide, salicylamide derivatives, β-peptoid- capped HDAC inhibitors, quinazoline derivatives, benzimidazole and benzothiazole derivatives, and β- elemene scaffold containing HDAC inhibitors. Most of the scaffolds have shown attractive IC50 (μM) in various cell lines like HDAC1, HDAC2, HDAC6, PI3K, HeLa, MDA-MB-231, MCF-10A, MCF-7, U937, K562 and Bcr-Abl cell lines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current drug discovery technologies - (2024) vom: 23. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Roshani [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer cells |
|---|
| Anmerkungen: |
Date Revised 28.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0115701638286941240217102948 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369054164 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369054164 | ||
| 003 | DE-627 | ||
| 005 | 20240229171814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115701638286941240217102948 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM369054164 | ||
| 035 | |a (NLM)38415493 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patel, Roshani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discovery and Development of HDAC Inhibitors |b Approaches for the Treatment of Cancer a Mini-review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Histone deacetylase (HDAC) inhibitors have emerged as promising cancer therapeutics due to their ability to induce differentiation, cell cycle arrest, and apoptosis in cancer cells. In the present review, we have described the systemic discovery and development of HDAC inhibitors. Researchers across the globe have identified various small molecules like benzo[d][1,3]dioxol derivatives, belinostat analogs, pyrazine derivatives, quinazolin- 4-one-based derivatives, 2,4-imidazolinedione derivatives, acridine hydroxamic acid derivatives, coumarin derivatives, tetrahydroisoquinoline derivatives, thiazole-5-carboxamide, salicylamide derivatives, β-peptoid- capped HDAC inhibitors, quinazoline derivatives, benzimidazole and benzothiazole derivatives, and β- elemene scaffold containing HDAC inhibitors. Most of the scaffolds have shown attractive IC50 (μM) in various cell lines like HDAC1, HDAC2, HDAC6, PI3K, HeLa, MDA-MB-231, MCF-10A, MCF-7, U937, K562 and Bcr-Abl cell lines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Histone deacetylase inhibitors | |
| 650 | 4 | |a IC50 (μM) | |
| 650 | 4 | |a cancer cells | |
| 650 | 4 | |a development | |
| 650 | 4 | |a discovery | |
| 650 | 4 | |a small molecules. | |
| 700 | 1 | |a Modi, Arjun |e verfasserin |4 aut | |
| 700 | 1 | |a Vekariya, Hitesh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug discovery technologies |d 2004 |g (2024) vom: 23. Feb. |w (DE-627)NLM160661455 |x 1875-6220 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115701638286941240217102948 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 02 | ||